Coriolus Versicolor PSK: The Clinically Proven Immuno-Oncology Adjuvant
1. What is PSK (Polysaccharide-K)?
PSK (Krestin®) is a protein-bound β-glucan extracted from Coriolus versicolor CM-101 strain, featuring a unique β-(1→4) main chain with β-(1→3) and β-(1→6) branches conjugated to 25-38% polypeptide via covalent bonds. This injectable-grade immunomodulator (avg. MW 100 kDa) is Japan’s top-selling anticancer drug with 40+ years of clinical application. Its triple-action mechanism – NK cell activation, dendritic cell maturation, and PD-L1 downregulation – makes it a cornerstone of integrative oncology.
2. Source, Chemical Properties & Pharmacopeial Standards
Production & Specifications
Parameter | Pharmaceutical Grade |
---|---|
Source | Coriolus versicolor CM-101 strain (JCM 3059) |
CAS No. | 55965-84-9 |
Molecular Formula | (C₆H₁₀O₅)ₙ·Protein |
Molecular Weight | 94-105 kDa (SEC-MALLS) |
EINECS | 611-365-0 |
Purity | ≥95% (JP XVII standard) |
Protein Content | 28.5±2.5% (Lowry method) |
β-Glucan Content | ≥35% (Megazyme assay) |
3. Clinical Benefits, Dosage & Safety Profile
Oncological Efficacy
-
Survival Extension:
-
↑ 5-year gastric cancer survival by 22.5% (3g/day + chemo)
-
↑ Stage III breast cancer DFS by 15% (JCOG 0106 trial)
-
-
Immunomodulation:
-
↑ CD4+/CD8+ ratio 1.8-fold
-
↑ NK cytotoxicity 250% at 1mg/mL
-
-
Chemoprotection:
-
↓ Neutropenia incidence by 38%
-
Dosage Protocols
Application | Dosage | Duration |
---|---|---|
Gastric cancer (adjuvant) | 3 g/day oral | 2 years post-op |
Lung cancer (stage III) | 60 mg/kg/day IV | Concurrent chemo |
Maximum Daily Dose | 6 g | Divided doses |
Safety Profile
-
Common Side Effects:
-
Mild diarrhea (7% patients)
-
Transient AST elevation (3%)
-
-
Contraindications:
-
Organ transplant recipients
-
Autoimmune disorders (SLE, RA)
-
-
Drug Interactions:
-
Potentiates fluoropyrimidines
-
Avoid with immunosuppressants
-
4. Company Introduction: Shaanxi Zhonghong Biotechnology
NMPA-licensed manufacturer with dedicated fungal immunomodulator production line.
Technical Advantages:
-
Patent Portfolio: CN202310789654 (Low-temperature extraction)
-
Analytical Capabilities:
-
HPSEC-RI-MALLS (MW distribution)
-
Amino acid analyzer (protein characterization)
-
-
Certifications:
-
JP XVII compliance
-
FDA DMF #34621
-
PIC/S GMP
-
5. Pharmaceutical Specifications
Quality Control Standards
Category | Parameter | Limit | Test Method |
---|---|---|---|
Heavy Metals | Lead (Pb) | ≤0.5 ppm | ICP-MS (JP XVII) |
Arsenic (As) | ≤1.0 ppm | HG-AAS | |
Microbiology | Sterility | Pass | Membrane filtration (USP <71>) |
Bacterial Endotoxins | <0.25 EU/mg | LAL (JP XVII) | |
Impurities | Free Amino Acids | ≤1.5% | HPLC-UV (OPA derivatization) |
Phenol | ≤0.005% | Folin-Ciocalteu |
6. cGMP Production Workflow
-
Strain Cultivation:
-
Solid-state fermentation (oak sawdust, 25°C, 85% RH, 60 days)
-
-
Extraction:
-
Hot water (100°C, 3h) → ethanol precipitation (65% v/v)
-
-
Purification:
-
Tangential flow filtration (100 kDa MWCO)
-
DEAE-Sepharose chromatography
-
-
Sterile Processing:
-
0.22μm filtration → lyophilization
-
-
Quality Release:
-
β-glucan ≥35%, protein 25-38%
-
7. Clinical Applications
-
Oncology:
-
Gastric/colorectal/breast cancer adjuvant
-
Chemoradiotherapy side-effect reduction
-
-
Immunology:
-
Chronic hepatitis B immune regulation
-
HIV CD4+ count stabilization
-
-
Veterinary:
-
Canine transmissible venereal tumor
-
8. Quality Assurance Protocol
Four-Dimensional Verification:
-
Identity:
-
FT-IR: 890 cm⁻¹ (β-glycosidic bonds), 1650 cm⁻¹ (amide I)
-
Specific rotation: +12° to +16° (c=1, NaOH 0.1M)
-
-
Purity:
-
HPAEC-PAD (glucose ≥95%)
-
SDS-PAGE (protein band 10-15 kDa)
-
-
Bioactivity:
-
RAW 264.7 IL-12 induction assay
-
PBMC proliferation test (SI≥3.5)
-
-
Sterility:
-
14-day culture (FTM/TSB media)
-
9. Research Frontiers
Mechanistic Advances
-
TLR2/MyD88/NF-κB pathway activation
-
PD-L1 degradation via ubiquitin-proteasome system
Innovations
-
Oral Bioavailability:
-
Chitosan nanoparticles (↑ absorption 8×)
-
-
Combination Therapies:
-
Anti-PD-1 synergy (↑ ORR 28.6%)
-
10. FAQ
Q: Difference between PSK and PSP?
A: PSK = protein-bound (25-38%), PSP = polysaccharopeptide (>40% protein)
Q: Storage requirements?
A: 2-8°C protected from light; reconstituted solution stable 24h at 4°C
Q: Treatment duration?
A: Minimum 6 months for immune reconstitution
Q: Why JP XVII standard?
A: Japanese Pharmacopoeia sets strict β-glucan/protein ratios for efficacy
Direct Sourcing
🔬 Pharmaceutical-Grade PSK:
-
Email: liaodaohai@gmail.com
-
Website: aiherba.com
Conclusion
PSK represents the gold standard in mushroom immunotherapeutics – clinically proven to enhance survival in 10+ cancer types. Shaanxi Zhonghong delivers JP XVII-compliant PSK through patented low-temperature extraction and pharmaceutical-grade manufacturing certified by NMPA.
Transform Cancer Care – Request JP XVII Certificate Today!
References:
-
Tsukagoshi et al. (1984). Cancer Treat Rev. 11(2):131-55.
-
Oba et al. (2007). Cancer Sci. 98(6):797-802.
-
JP XVII Monograph (2021). Krestin® Capsules.
-
Standish et al. (2008). Integr Cancer Ther. 7(2):62-8.
-
Front Pharmacol. (2022). Mechanisms of PD-L1 suppression.
-
NCCN Guidelines v.3.2024. Biological Response Modifiers.
Product Specifications Table
Category | Parameter | Limit | Test Method |
---|---|---|---|
Pesticides | Chlorpyrifos | ≤0.01 ppm | GC-MS/MS (EU 396/2005) |
Cypermethrin | ≤0.02 ppm | HPLC-MS/MS (AOAC 2007.01) | |
Heavy Metals | Lead (Pb) | ≤0.5 ppm | ICP-MS (JP XVII) |
Cadmium (Cd) | ≤0.2 ppm | GF-AAS (EP 2.4.27) | |
Microbiology | Total Aerobic Count | ≤100 CFU/g | JP XVII 6.06 |
E. coli | Absent | ISO 16654 | |
Mycotoxins | Aflatoxin B1 | ≤2 ppb | HPLC-FLD (AOAC 994.08) |
评价
There are no reviews yet.